Abstract High pharmaceutical pricing practices in Europe have been increasingly on the radar of European Union, academia and civil society as a risk to Member State health budgets. It is therefore hardly surprising that, recent years, competition authorities resuscitated excessive prohibition contained Article 102(a) TFEU. Focusing this phenomenon, piece highlights diverse ways which United Bra...